The landscape of early-stage biotech venture capital is perpetually evolving, shaped by scientific breakthroughs, market pressures, and investor sentiment. In recent years, the sector has witnessed both exuberant investment in technological platforms, such as artificial intelligence (AI)-driven drug discovery, and subsequent periods of recalibration, where the fundamental tenets of therapeutic development—strong biology, clinical validation, and clear paths to market—have reasserted their primacy. This cyclical refocusing underscores a critical challenge for investors: how to identify genuinely transformative science amidst a sea of promise and efficiently shepherd it to meaningful value inflection points.
Against this backdrop, the recent close of Arkin Bio Ventures III (ABV III), a $100 million fund from the life sciences arm of investment manager Arkin Capital, signals a confident bet on a rigorous, hands-on investment philosophy. The fund targets advanced pre-clinical to early clinical-stage biotech companies, specifically those developing therapies in oncology, immunology, inflammation, and rare diseases. While the fund’s thematic focus aligns with areas of high unmet medical need and commercial interest, its differentiated edge lies in its operational model. Arkin Bio emphasizes being a “true partner from day one,” leveraging deep scientific expertise and active portfolio support to bridge the perilous gap between promising data and proof-of-concept in patients.
To understand the strategy and ethos behind this new vehicle, Drug and Device World spoke with Dr. Pini Orbach, Managing Partner at Arkin Bio, who leads ABV III. Orbach combines scientific rigor with investment expertise, playing a key role in establishing Arkin Bio’s success. The company has supported firms such as Keros Therapeutics, Bluejay Therapeutics, HI-Bio (acquired by Biogen), UroGen Pharma, and Censa Pharmaceuticals (acquired by PTC). Most recently, the phenylketonuria (PKU) therapy developed by Censa got US Food and Drug Administration (FDA) approval. In the interview, Orbach delineates the fund’s “no-BS,” data-centric approach, discusses the nuanced evaluation of risk, and explains why, in an age of AI hype, the quality of the underlying biological data and the strength of the team remain non-negotiable.
This interview has been edited for clarity, consistency, and length.
Dr. Phalguni Deswal [PD]: Dr. Orbach, your press release for Arkin Bio Ventures III notes that while AI and computational tools are promising, the foundation of therapeutics remains strong biology and proven clinical results. In practice, how does this philosophy shape your evaluation of a potential investment? What makes an asset “truly worth it” to you?
Dr. Pini Orbach: We are therapeutics-focused investors. The means by which a company discovers or develops a drug—be it through an AI platform, traditional screening, or something else—is interesting, but it is not the key factor for us. If an AI platform allows them to develop innovative drugs, that’s great. However, the validation for any platform, AI or otherwise, ultimately happens in the clinic. We will only truly know its value when we reach proof-of-concept in patients.
So, in a way, we are somewhat agnostic to how you get to the drug candidate. What we care deeply about is that the drug itself is innovative and has a clear, differentiated advantage over what exists in the market. We look at the platform, we understand it, and we appreciate advanced technology. But we are data-driven investors, not AI investors. Show me the compelling biological data for the drug itself. For us as drug developers, the AI can sometimes be a “black box”; we focus on what comes out of it and the evidence supporting its clinical potential.
PD: Arkin Bio promotes itself as an active, “true partner from day one,” working closely with founders on biological strategy and clinical positioning. Drawing from your experience with prior funds, what are the most common strategic gaps you help founders fill?
Dr. Pini Orbach: We are active investors. That means we don’t just provide capital; we help companies reach critical inflection points in their development. We do this primarily through board participation and, often, more frequent engagement—weekly or monthly meetings with management to help them tackle whatever challenges arise.
The gaps can vary. It might be a development gap, a financing gap, or a regulatory gap. Having been involved in drug development for many years across numerous disease areas, we’ve encountered a wide array of challenges. This experience is what we bring to the table.
A good example from our past is Censa Pharmaceuticals. It was a Boston-based company with a drug for PKU that, at the time, no other professional investor wanted to touch. We were the sole professional investor. We helped them navigate the clinical path, were active at the board level, and stayed supportive even when an initial option agreement with a larger company fell through—a significant negative event. We continued to back them, eventually helping to sell the company to PTC Therapeutics. That drug is now approved in the US and Europe and is projected to be a blockbuster. We look for these kinds of opportunities—companies that may not be in the mainstream spotlight but where we have the ability to see the potential and guide them to an approved drug. Bringing therapies to market is a key driver for us beyond financial returns.
PD: You aim to bring companies to “meaningful value milestones.” For an early-stage asset, what does a compelling proof-of-concept package look like to Arkin? Is it purely clinical data, or does it encompass broader strategic elements?
Dr. Pini Orbach: It starts with the science. We get excited by a differentiated drug mechanism. Then we scrutinize the existing data, which at this stage is usually preclinical data from animal models. A critical question is: do these animal models truly translate to human patients? Not all diseases have good translational models. We analyze the data to deduce the potential for efficacy in humans, which might also include looking at data from human cell assays.
We also conduct a thorough risk assessment. Safety is paramount—it’s a bigger concern in chronic non-oncology diseases than in oncology, though still important there. We analyze the intellectual property protection, the clinical development pathway, and the market potential. If it’s a very rare disease, the trial might be small and quick, but then you must ask: what is the commercial potential? If there are only 1,000 patients worldwide, how do you price the drug and reach them?
We try to address all these questions from the beginning. You must predict, based on data and market understanding, whether the drug will be competitive and attractive to potential acquirers or downstream investors in five years. You need a kind of “crystal ball.” Our goal is to invest in companies where, with the current round of funding, they can reach that proof-of-concept in patients without necessarily needing an additional financing round just to get there.
PD: ABV III will focus on oncology, immunology, inflammation, and rare diseases. Is this portfolio mix driven primarily by market logic, by synergies within your existing network, or do you evaluate each opportunity as a standalone?
Dr. Pini Orbach: We evaluate each opportunity on its own merits. That said, we are naturally influenced by the broader market flow and excitement. Currently, inflammatory and autoimmune diseases are a hot area for big pharma, and oncology is perpetually relevant. However, even within hot areas, we try not to follow the herd. We aim to identify the next generation of therapies, not just more of the same.
As a fund manager, I also must balance the portfolio’s risk profile. Ideally, we create a mix: some higher-risk, high-reward investments alongside others that may be technologically de-risked but carry commercial or execution challenges. This diversification helps ensure that if some projects face hurdles, others can succeed.
I can share that we’ve already made our first investment from ABV III, which is a good example of our independent thinking. It’s in a Boston-based company developing a gene therapy for hearing loss in children. Gene therapy as a field has faced some negative sentiment recently due to safety setbacks with systemic delivery. However, we analyzed this specific case: it’s a localized injection into the inner ear, which minimizes systemic risk, and other companies have shown promising early data in hearing loss without major safety issues. We felt it was a worthwhile, meaningful investment that also fits a de-risked profile within a challenged sector. It’s exactly the kind of nuanced opportunity we seek.
PD: Beyond compelling science, what do you look for in an early-stage company and its team? What are the non-negotiable pillars?
Dr. Pini Orbach: First, a strong scientific foundation is an absolute must. Second, a very strong, execution-oriented team. Third, we need to be convinced the therapeutic has the potential to be “best-in-class” and truly game-changing for patients.
Those are the main ingredients. Beyond that, we look for a clear development plan where the capital we provide is sufficient to reach a significant value inflection point, ideally clinical proof-of-concept, within a reasonable timeframe—say, one to two years. We prefer situations where the current funding round is adequate to get to that milestone without an immediate need for another raise. We want to see a path to a meaningful data readout that will fundamentally change the company’s valuation and prospects.
PD: How would you summarize the core identity or “takeaway” of Arkin Bio Ventures III for founders who might consider pitching to you or for observers in the ecosystem?
Dr. Pini Orbach: Others have told me we are a “no-BS” fund. We are very straightforward, science-driven, pragmatic, and practical. We move quickly if we like an opportunity. If you have something that is genuinely best-in-class, backed by compelling high-quality data—even if it’s preclinical—and not just an imaginative story on a slide, you should approach us.
We have a reputation for being supportive, positive investors. We’ve proven we can take companies others have passed on and help turn them into success stories, like Censa, Keros, and UroGen. We are pragmatic and focused on high quality. This reputation generates strong deal flow for us, including from the US, even though we are based in Israel. When we present a portfolio company to big pharma or other investors, they know it has undergone rigorous scrutiny. We don’t waste time on socializing without substance; our engagements are high-quality exchanges about real opportunities. That’s the reputation we strive to maintain and the partner we aim to be for founders.
